The TAB1 Knockout A2780 Cell Line is a CRISPR/Cas9-edited human ovarian adenocarcinoma cell model engineered for loss-of-function studies of the TGF-beta-activated kinase 1 (TAK1) binding protein 1 (TAB1) gene. This stable knockout cell line provides a reliable experimental system to dissect the role of TAB1 in pro-inflammatory and stress-responsive signaling networks without the confounding effects of wild-type gene expression. By disrupting the TAB1 locus, this product enables researchers to examine TAB1-dependent molecular mechanisms in a well-characterized ovarian cancer background.
The host A2780 cell line is an established human ovarian carcinoma model originally derived from an untreated patient, displaying epithelial morphology and widely used in cancer biology research. A2780 cells retain key features of ovarian cancer, including responsiveness to cytokines and chemotherapeutic agents, making them suitable for investigating signaling pathways implicated in tumor progression and drug resistance. This background is particularly relevant for TAB1 knockout studies because ovarian cancers often exhibit aberrant activation of TAK1-mediated pathways, contributing to malignant phenotypes such as increased proliferation, apoptosis resistance, and metastatic potential.
TAB1 acts as an adaptor that binds and activates TAK1 (MAP3K7), a kinase essential for inflammatory and stress signaling. Upon stimulation with IL-1, TNF-??, TGF-??, or TLR ligands, TAB1 associates with TRAF6 in receptor-proximal complexes, promoting TAK1 autophosphorylation and activation. Activated TAK1 phosphorylates the IKK complex, driving NF-??B nuclear translocation, and also activates JNK and p38 MAPK cascades. These pathways control transcription of genes involved in inflammation, survival, and immune responses via AP-1. TAB1 also interacts with TAB2, TAB3, XIAP, and p38??, fine-tuning TAK1 signaling magnitude and specificity. Consequently, TAB1 serves as a crucial link between extracellular inflammatory stimuli and intracellular transcriptional reprogramming.
In the A2780 ovarian cancer context, constitutive or cytokine-driven activation of NF-??B, JNK, and p38 MAPK pathways promotes tumor cell survival, invasion, and resistance to platinum-based chemotherapies. By eliminating TAB1 expression, this knockout line enables unambiguous separation of TAK1-dependent from TAK1-independent signaling events. It provides a clean genetic background to study the dependency of ovarian cancer cells on TAB1?CTAK1 signaling for proliferation, anchorage-independent growth, and response to DNA-damaging agents. Moreover, the model facilitates identification of potential synthetic lethal interactions or compensatory signaling nodes that could be therapeutically exploited.
Researchers can use this TAB1 knockout line in diverse assays. Western blotting and phospho-TAK1 ELISA quantify TAK1 activation and downstream signaling. Co-immunoprecipitation probes altered interactions within the TAB?CTAK1?CTRAF6 complex. NF-??B reporter and cytokine stimulation assays provide functional pathway readouts. Phenotypic assays such as transwell invasion and cell viability link molecular changes to cancer cell behavior. This line is ideal for ovarian cancer signaling studies, inflammatory pathway dissection, drug resistance research, and metastasis modeling. For further information, please contact Ascent Research.
